Shares of Zealand Pharma A/S experienced a severe sell-off on Friday, plummeting 32.53% to 249.10 Danish kroner by mid-morning trading in Copenhagen. The dramatic decline followed the release of new clinical trial data for the company's experimental obesity treatment, petrelintide, which disappointed investors and wiped approximately 8.3 billion kroner ($1.3 billion) from the biotech's market capitalization.
Clinical Results and Competitive Landscape
The Phase 2 study involved 493 overweight or obese adults without type 2 diabetes over a 42-week period. Results showed petrelintide, an amylin analogue designed to mimic a natural satiety hormone, led to a maximum weight loss of 10.7%, compared to a 1.7% loss in the placebo group. While the company highlighted the drug's tolerability profile, the efficacy data placed it significantly behind a key competitor. Eli Lilly's similar amylin-based drug, eloralintide, demonstrated up to 20.1% weight reduction over 48 weeks in a comparable mid-stage trial.
Analysts were quick to note the competitive challenge. Jefferies labeled petrelintide as "second-best to Lilly's elora for now," while KBC Securities suggested the outcome complicates any ambition for a first-line treatment position in the lucrative obesity market. The sector is currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both GLP-1 receptor agonists.
Strategic Partnership and Market Implications
The data carries high stakes for Zealand and its partner, Roche. Last year, Roche entered a licensing agreement for petrelintide valued at up to $5.3 billion, a deal central to the Swiss pharmaceutical giant's strategy to secure a top-three position in the weight-loss drug market. Zealand's Chief Executive Officer, Adam Steensberg, framed the results as a step toward developing obesity drugs that "fit the lives they actually want to live," emphasizing patient experience over pure efficacy metrics.
Chief Medical Officer David Kendall pointed to the double-digit weight loss and what he termed an "exceptional tolerability profile." The company reported that among participants on the highest dose, there were zero cases of vomiting and not a single discontinuation due to gastrointestinal side effects, a common issue with current obesity medications. Furthermore, 98% of patients reached the target maintenance dose.
Data Nuances and Future Plans
Morningstar analyst Karen Andersen highlighted nuances in the trial comparisons, noting that women constituted 53% of participants in Zealand's study versus 78% in Lilly's trial. Zealand also informed analysts that its female subjects, after placebo adjustment, achieved roughly six percentage points more weight loss than male participants.
Looking ahead, Zealand plans to present more detailed data at a scientific meeting later this year. A Phase 3 clinical trial for petrelintide, which the company will conduct in-house, remains scheduled to begin in the second half of 2026. Additionally, a Phase 2 trial combining petrelintide with Roche's CT-388 is set to start in the first half of 2026.
Investor Sentiment and Sector Volatility
Friday's market reaction underscores the volatility and high expectations within the obesity drug development sector. Investors are demonstrating little patience for pipeline candidates that appear to lag behind the current frontrunners. This sentiment was evident last month when Novo Nordisk's stock also faced pressure after its next-generation candidate, CagriSema, trailed Lilly's therapy in direct testing.
The risk for Zealand and Roche is clear. Should upcoming data or the Phase 3 results fall short on weight loss, tolerability, or patient retention, petrelintide could struggle to compete effectively. For now, the market has judged Zealand's latest data as a win for tolerability but not for knockout weight loss efficacy, leading to a sharp repricing of the stock and resetting expectations for its role in the competitive obesity treatment race.
